Skip to main content


To gain further insight into the mechanism by which lactobacilli develop antimicrobial activity, we have examined how Lactobacillus acidophilus LB inhibits the promoted cellular injuries and intracellular lifestyle of Salmonella enterica serovar Typhimurium SL1344 infecting the cultured, fully differentiated human intestinal cell line Caco-2/TC-7. We showed that the spent culture supernatant of strain LB (LB-SCS) decreases the number of apical serovar Typhimurium-induced F-actin rearrangements in infected cells. LB-SCS treatment efficiently decreased transcellular passage of S. enterica serovar Typhimurium. Moreover, LB-SCS treatment inhibited intracellular growth of serovar Typhimurium, since treated intracellular bacteria displayed a small, rounded morphology resembling that of resting bacteria. We also showed that LB-SCS treatment inhibits adhesion-dependent serovar Typhimurium-induced interleukin-8 production.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus LBReduced Apical Salmonella-Induced F-actin RearrangementsBeneficial
Lactobacillus LBReduced Salmonella-Induced Interleukin-8 ProductionBeneficial
Lactobacillus LBReduced Transcellular Passage of SalmonellaBeneficial
Lactobacillus LBReduction in Intracellular Salmonella LevelsBeneficial

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at